How Asian Drugmakers Are Imbibing ML Into Their Frameworks- AIM

Small molecule discovery, binding affinity prediction and medical prescription are the three fields which artificial intelligence seems to have invaded in the pharmaceutical space. Deep Intelligent Pharma (DIP) focuses mainly on building software for providing medical transcription using AI. This Chinese company deploys natural language processing(NLP) frameworks to sift through the exhaustive regulatory documents and assist the pharma companies in manufacturing content which adheres to the law. These AI-enabled writing tools, including automated transcription, tabulated data analysis, document review, and quality control will be used to create content and documents to be submitted to regulatory bodies such as the Food and Drug Administration. The company has raised $26.1 million in funding from Sequoia Capital China and ZhenFund.